Dermata Competitors
| DRMA Stock | USD 1.82 0.05 2.82% |
Dermata Therapeutics vs Artelo Biosciences Correlation
Poor diversification
The correlation between Dermata Therapeutics and ARTL is 0.69 (i.e., Poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Dermata Therapeutics and ARTL in the same portfolio, assuming nothing else is changed.
Moving together with Dermata Stock
Moving against Dermata Stock
| 0.75 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.61 | DSGN | Design Therapeutics | PairCorr |
| 0.57 | KYTX | Kyverna Therapeutics | PairCorr |
| 0.44 | ENGN | enGene Holdings Common | PairCorr |
| 0.39 | 63E | ONWARD MEDICAL BV | PairCorr |
Dermata Therapeutics Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Dermata Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Dermata and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Dermata Therapeutics does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Dermata Stock performing well and Dermata Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Dermata Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| ATXI | 6.76 | (1.47) | 0.00 | (1.77) | 0.00 | 12.66 | 50.24 | |||
| WINT | 7.26 | (2.90) | 0.00 | (1.45) | 0.00 | 16.67 | 75.00 | |||
| CARM | 7.47 | 0.05 | 0.00 | 0.02 | 0.00 | 14.29 | 56.42 | |||
| PBM | 7.73 | (3.84) | 0.00 | (0.63) | 0.00 | 9.41 | 96.64 | |||
| LIPO | 8.18 | (0.69) | 0.00 | (0.62) | 0.00 | 17.14 | 94.73 | |||
| VRAX | 5.41 | (1.07) | 0.00 | (0.29) | 0.00 | 7.89 | 92.80 | |||
| ELAB | 5.70 | (3.69) | 0.00 | (1.18) | 0.00 | 5.71 | 53.38 | |||
| GTBP | 5.34 | (0.07) | 0.00 | (0.13) | 0.00 | 10.84 | 51.03 | |||
| REVB | 3.97 | (1.75) | 0.00 | (0.88) | 0.00 | 6.12 | 35.57 | |||
| ARTL | 5.35 | (0.88) | 0.00 | 11.97 | 0.00 | 7.86 | 41.63 |
Cross Equities Net Income Analysis
Compare Dermata Therapeutics and related stocks such as Avenue Therapeutics, Windtree Therapeutics, and Carisma Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WINT | (2.8 M) | (21 M) | (37.3 M) | (45.2 M) | (44.1 M) | (55.2 M) | (39.5 M) | (18.4 M) | (20.5 M) | (27.5 M) | (30.3 M) | (67.6 M) | (39.2 M) | (20.3 M) | (5.5 M) | (4.9 M) | (5.2 M) |
| CARM | (13 M) | (13 M) | (19.8 M) | (19.4 M) | (34.5 M) | (33.5 M) | 1.9 M | (29 M) | (33.7 M) | (107.5 M) | (28.3 M) | (336 K) | (61.2 M) | (86.9 M) | (60.5 M) | (54.4 M) | (57.2 M) |
| PBM | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8 M | (51.2 M) | 1 M | 910.6 K | 956.1 K |
| LIPO | (61.8 K) | (61.8 K) | (61.8 K) | (61.8 K) | (61.8 K) | (61.8 K) | (61.8 K) | (61.8 K) | (61.8 K) | (61.8 K) | (61.7 K) | (1.9 M) | (2.6 M) | (4.6 M) | (5 M) | (4.5 M) | (4.3 M) |
| VRAX | (801.1 K) | (801.1 K) | (801.1 K) | (801.1 K) | (801.1 K) | (801.1 K) | (801.1 K) | (801.1 K) | (801.1 K) | (801.1 K) | (651 K) | (1.7 M) | (5.5 M) | (6.7 M) | (6.1 M) | (5.5 M) | (5.7 M) |
| ELAB | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (784.7 K) | (1.8 M) | (4.3 M) | (6.2 M) | (5.6 M) | (5.3 M) |
| GTBP | 150 K | (3.7 M) | (5.2 M) | (501 K) | (23.5 M) | (21.5 M) | 9.8 M | (144.2 M) | (259.2 M) | (38.6 M) | (28.3 M) | (58 M) | (20.9 M) | (7.6 M) | (13.2 M) | (11.8 M) | (12.4 M) |
| REVB | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 6.2 M | 8.8 M | 16.3 M | 27.6 M | (3.6 K) | (136.4 K) | (12 M) | (10.8 M) | (120.3 K) | (15 M) | (13.5 M) | (12.9 M) |
| ARTL | (15.3 K) | (15.3 K) | (15.3 K) | (15.3 K) | (15.3 K) | (15.2 K) | (29.7 K) | (234.9 K) | (2.3 M) | (2.2 M) | (4.7 M) | (7.4 M) | (10.1 M) | (9.3 M) | (9.8 M) | (8.8 M) | (8.4 M) |
Dermata Therapeutics and related stocks such as Avenue Therapeutics, Windtree Therapeutics, and Carisma Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Dermata Therapeutics financial statement analysis. It represents the amount of money remaining after all of Dermata Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Dermata Therapeutics Competitive Analysis
The better you understand Dermata Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Dermata Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Dermata Therapeutics' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Dermata Therapeutics Competition Performance Charts
Five steps to successful analysis of Dermata Therapeutics Competition
Dermata Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Dermata Therapeutics in relation to its competition. Dermata Therapeutics' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Dermata Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Dermata Therapeutics' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Dermata Therapeutics, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Dermata Therapeutics position
In addition to having Dermata Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run SPAC Thematic Idea Now
SPAC
Entities that are involved in raising capital, merging with and acquiring companies, and investing in private equity through leveraged buyouts. The SPAC theme has 25 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize SPAC Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Dermata Therapeutics Correlation with its peers. For information on how to trade Dermata Stock refer to our How to Trade Dermata Stock guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dermata Therapeutics. Projected growth potential of Dermata fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Dermata Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Dermata Therapeutics's market price often diverges from its book value, the accounting figure shown on Dermata's balance sheet. Smart investors calculate Dermata Therapeutics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Dermata Therapeutics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Dermata Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Dermata Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Dermata Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.